According to The Fly, in a latest note to investors, a research analyst has provided a rating update for the Healthcare company, VBI Vaccines (VBV). The company recieved Buy rating from Brookline Capital Markets’ analyst Kumaraguru Raja.
Raja wrote:
“VBI Vaccines has entered into a license and collaboration agreement with the development of a therapeutic for Hepatitis-B infection using VBI Vaccines’ recombinant, protein-based immunotherapeutic VBI-2601. Brii is a China-based company and would now be eligible to develop and commercialize the planned therapeutic in and Taiwan. VBI has received an upfront payment of C$11M ($4M upfront and C$7M in equity investment priced at C$3.05/share). It should also receive another C$117.5M in potential milestone payments, and potential double- digit royalties from sales in the licensed territory.”
According to TipRanks.com, Raja is a 1-star analyst with an average return of -6.7% and a 35.1% success rate. Raja covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics Ltd, Corbus Pharmaceuticals, and Acer Therapeutics Inc.
Read also: Does Amarin’s (AMRN) Impending FDA Decision Matter?
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for VBI Vaccines.
Based on VBI Vaccines’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$20.09 million. In comparison, last year the company had a GAAP net loss of C$12.29 million.
VBI Vaccines, Inc. is a biopharmaceutical company, which develops vaccines for infectious disease and immuno-oncology. Its pipeline includes Sci-B-Vac, CMV Vaccine, GBM Immunotherapy, MB Immunotherapy, and Zika Vaccine. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
